Year : 2021 | Volume
: 6 | Issue : 2 | Page : 118--126
Chimeric antigen receptor T-Cell therapy: The way forward!
Sunil B Rajadhyaksha, Anisha A Navkudkar, Priti D Desai
Department of Transfusion Medicine, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
Various cytotoxic approaches for cancer therapy have been developed over the years. However, due to their limited efficacy, there is a continual search for therapeutic approaches with better outcomes, such as immunotherapy that develops and augments the patient's immune system. Chimeric Antigen Receptor (CAR) T-cell immunotherapy involves genetic modification of patient's own T-cells to express CAR exclusive for a tumor antigen. It involves bioengineering, ex vivo cell expansion, and re-infusion back to the patient. The application of CAR-T therapy is seen as a potential mainstay treatment for hematologic cancers, while it is still being explored for solid-organ malignancies. In this review, the rationale for the development of genetically modified T-cells, its generations, the process of preparing CAR T cells, challenges and potential strategies, limitations, and various clinical applications are described. Information for review was obtained from available material in Google and PubMed.
Dr. Sunil B Rajadhyaksha
Department of Transfusion Medicine, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra
|How to cite this article:|
Rajadhyaksha SB, Navkudkar AA, Desai PD. Chimeric antigen receptor T-Cell therapy: The way forward!.Glob J Transfus Med 2021;6:118-126
|How to cite this URL:|
Rajadhyaksha SB, Navkudkar AA, Desai PD. Chimeric antigen receptor T-Cell therapy: The way forward!. Glob J Transfus Med [serial online] 2021 [cited 2022 Jan 25 ];6:118-126
Available from: https://www.gjtmonline.com/article.asp?issn=2468-8398;year=2021;volume=6;issue=2;spage=118;epage=126;aulast=Rajadhyaksha;type=0